Glenmark-backed biotech firm unveils new cancer drug candidate for solid tumours
Ichnos Glenmark Innovation, Inc. (IGI), a global clinical-stage biotechnology company focused on developing multispecific antibodies in oncology, has announced a new development candidate, ISB 2301, for the potential treatment of multiple solid tumour indications. According to a press release filed with the NSE, the company said ISB 2301 is a first-in-class multispecific immune cell activator…
